Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Cash: 2016-2025

Historic Change in Cash for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $29.1 million.

  • Akebia Therapeutics' Change in Cash rose 632.35% to $29.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.4 million, marking a year-over-year increase of 1160.93%. This contributed to the annual value of $9.0 million for FY2024, which is 118.46% up from last year.
  • Per Akebia Therapeutics' latest filing, its Change in Cash stood at $29.1 million for Q3 2025, which was up 21.73% from $23.9 million recorded in Q2 2025.
  • In the past 5 years, Akebia Therapeutics' Change in Cash ranged from a high of $61.5 million in Q1 2025 and a low of -$57.4 million during Q4 2021.
  • For the 3-year period, Akebia Therapeutics' Change in Cash averaged around $6.8 million, with its median value being -$2.5 million (2024).
  • In the last 5 years, Akebia Therapeutics' Change in Cash tumbled by 919.93% in 2023 and then spiked by 6,527.27% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Change in Cash (Quarterly) stood at -$57.4 million in 2021, then rose by 4.75% to -$54.7 million in 2022, then spiked by 93.42% to -$3.6 million in 2023, then spiked by 596.30% to $17.9 million in 2024, then surged by 632.35% to $29.1 million in 2025.
  • Its Change in Cash was $29.1 million in Q3 2025, compared to $23.9 million in Q2 2025 and $61.5 million in Q1 2025.